Clinical bottom line
Acute viral bronchiolitis in pediatric primary care settings is predominantly a self-limited illness best managed with supportive care, including hydration and oxygenation as needed. Evidence consistently discourages routine use of bronchodilators, corticosteroids, antibiotics, or other pharmacologic interventions due to lack of efficacy. Implementation of guideline-based management and multifaceted education programs can reduce unnecessary treatments and improve adherence to evidence-based practices. Close monitoring and appropriate referral for severe cases remain essential.
What the evidence shows
Bronchiolitis, primarily caused by respiratory syncytial virus (RSV), is a leading cause of lower respiratory tract infection in infants and young children. Porcaro et al. (2023) highlight that in Italian primary care, adherence to bronchiolitis guidelines emphasizing supportive care is variable, with overuse of non-recommended therapies persisting. This reflects a broader international pattern.
Multifaceted educational interventions targeting clinicians have demonstrated effectiveness in improving adherence to evidence-based bronchiolitis management. Murch et al. (2015) reported that structured education reduced inappropriate use of bronchodilators and corticosteroids in acute viral bronchiolitis.
Davis et al. (2018) further showed that coordinated efforts across care settings, including primary care, emergency departments, and inpatient units, can increase evidence-based management rates, reducing unnecessary interventions and healthcare costs.
Dellplain et al. (2022) compared treatment patterns across primary, tertiary, and urgent care settings, finding that primary care providers often prescribe bronchodilators and antibiotics more frequently than recommended, underscoring the need for targeted guideline dissemination.
Overall, current guidelines recommend supportive care with nasal suctioning, hydration, and supplemental oxygen for hypoxemia. Routine use of bronchodilators, corticosteroids, hypertonic saline, or antibiotics is not supported by high-quality evidence in typical cases (Porcaro et al., 2023; Davis et al., 2018).
Caveats and uncertainty
Despite clear guidelines, variability in clinical practice persists, partly due to diagnostic uncertainty, parental expectations, and clinician habits (Porcaro et al., 2023). Some children with underlying comorbidities or severe disease may require individualized management beyond standard recommendations.
Most studies focus on infants under 12 months; evidence in older children with bronchiolitis is less robust. Additionally, the impact of emerging viral variants and co-infections on disease course and management remains under investigation.
Educational interventions require sustained effort and resources to maintain long-term practice change, and their effectiveness may vary by healthcare system and setting (Murch et al., 2015).
How this may change practice
Primary care clinicians should prioritize supportive care and avoid routine pharmacologic treatments in infants with typical bronchiolitis presentations. Emphasizing hydration, nasal clearance, and oxygen supplementation when indicated aligns with best evidence.
Incorporating multifaceted education and guideline dissemination strategies can improve adherence and reduce unnecessary prescribing. Clinicians should engage caregivers with clear communication about the natural course of bronchiolitis and signs warranting further evaluation.
Developing local protocols and quality improvement initiatives may help standardize care and reduce practice variability. Close follow-up and timely referral for children with severe respiratory distress or risk factors remain critical.